Impact of pre-existing cross-reactive antibodies on cyclic dengue outbreaks in the hyperendemic region of Bali, Indonesia.

Autor: Balingit JC; Department of Tropical Viral Vaccine Development, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan., Denis D; Exeins Health Initiative (EHI), Jakarta 12870, Indonesia., Suzuki R; Department of Virology II, National Institute of Infectious Diseases, Tokyo 208-0011, Japan., Hayati RF; Exeins Health Initiative (EHI), Jakarta 12870, Indonesia., Ngwe Tun MM; Department of Tropical Viral Vaccine Development, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan; Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan; Center for Vaccines and Therapeutic Antibodies for Emerging Infectious Diseases, Shimane University, Izumo 690-8504, Japan., Takamatsu Y; Department of Tropical Viral Vaccine Development, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan; Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan., Masyeni S; Department of Internal Medicine, Faculty of Medicine and Health Science, Universitas Warmadewa, Bali 80239, Indonesia., Sasmono RT; Eijkman Research Center for Molecular Biology, National Research and Innovation Agency (BRIN), Jakarta 10340, Indonesia., Morita K; Department of Tropical Viral Vaccine Development, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan; Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan; DEJIMA Infectious Disease Research Alliance, Nagasaki University, Nagasaki 852-8523, Japan. Electronic address: kmorita@nagasaki-u.ac.jp.
Jazyk: angličtina
Zdroj: Virus research [Virus Res] 2024 Oct; Vol. 348, pp. 199445. Date of Electronic Publication: 2024 Aug 03.
DOI: 10.1016/j.virusres.2024.199445
Abstrakt: The four serotypes of the dengue virus (DENV) cause a range of diseases ranging from mild fever to severe conditions. Understanding the immunological interactions among the four serotypes is crucial in comprehending the dynamics of serotype shifting during outbreaks in areas where all four serotypes co-circulate. Hence, we evaluated the neutralizing antibody and antibody-dependent enhancement responses against the four DENV serotypes using acute-phase plasma samples collected from 48 laboratory-confirmed dengue patients during a dengue outbreak in Bali, Indonesia in 2022. Employing single-round infectious particles to exclusively investigate immunogenicity to the structural surface proteins of DENV, which are the targets of antibodies, we found that individuals with a probable prior history of DENV-1 infection exhibited increased susceptibility to secondary DENV-3 infection, attributed to cross-reactive antibodies with limited neutralizing activity against DENV-3 (geometric mean 50 % neutralization titer (GMNT 50 ) = 47.6 ± 11.5). This susceptibility was evident in vitro, with a mean fold enhancement of 28.4 ± 33.9. Neutralization titers against DENV-3 were significantly lower compared to other serotypes (DENV-1 GMNT 50 = 678.1 ± 9.0; DENV-2 GMNT 50 = 210.5 ± 8.7; DENV-4 GMNT 50 = 95.14 ± 7.0). We demonstrate that prior immunity to one serotype provides limited cross-protection against the other serotypes, influencing the dominant serotype in subsequent outbreaks. These findings underscore the complexity of dengue immunity and its implications for vaccine design and transmission dynamics in hyperendemic regions.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: